Answers are grounded in this paper and cite their sources.
This review summarizes the pharmacological perspective on antiplatelet therapy, highlighting the development of new agents like prasugrel, ticagrelor, and PAR-1 antagonists to overcome interindividual variability and bleeding risks.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jan Bultas (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: